Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E18.36 EPS (ttm)17.13 Insider Own0.10% Shs Outstand219.12M Perf Week2.44%
Market Cap68.92B Forward P/E15.10 EPS next Y20.84 Insider Trans-13.56% Shs Float218.50M Perf Month2.06%
Income3.82B PEG2.14 EPS next Q5.01 Inst Own88.40% Short Float0.99% Perf Quarter37.64%
Sales11.24B P/S6.13 EPS this Y24.00% Inst Trans-0.07% Short Ratio1.22 Perf Half Y23.74%
Book/sh52.05 P/B6.04 EPS next Y3.67% ROA18.50% Target Price344.61 Perf Year15.52%
Cash/sh17.33 P/C18.15 EPS next 5Y8.57% ROE36.60% 52W Range223.02 - 333.65 Perf YTD2.67%
Dividend- P/FCF21.43 EPS past 5Y31.30% ROI23.50% 52W High-6.78% Beta0.94
Dividend %- Quick Ratio2.60 Sales past 5Y17.90% Gross Margin88.20% 52W Low39.47% ATR6.55
Employees7350 Current Ratio3.00 Sales Q/Q11.70% Oper. Margin47.90% RSI (14)53.61 Volatility1.88% 1.98%
OptionableYes Debt/Eq0.57 EPS Q/Q21.60% Profit Margin34.00% Rel Volume0.37 Prev Close314.53
ShortableYes LT Debt/Eq0.57 EarningsOct 20 BMO Payout0.00% Avg Volume1.76M Price311.05
Recom2.10 SMA201.29% SMA501.91% SMA20012.74% Volume333,981 Change-1.11%
Sep-06-16Downgrade Jefferies Buy → Hold
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Sep-28-16 11:45AM  Instant Analysis: Biogen's Agreement With Anavex Life Sciences at Motley Fool
11:15AM  Anavex Soars on Biogen Agreement
11:01AM  Will Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis? at Motley Fool
10:54AM  Newbie Anavex Rockets On Testing Deal With IBD 50 Stock Biogen
09:39AM  ETFs with exposure to Biogen, Inc. : September 28, 2016
07:00AM  Anavex Compound to be Tested in Biogen Neurological Protection Model GlobeNewswire
Sep-27-16 10:12AM  Ionis/Biogen Complete Nusinersen NDA Submission in U.S.
07:50AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
Sep-26-16 07:30AM  Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy Business Wire
Sep-23-16 07:35PM  [$$] Rodin Therapeutics, a Neurology Drug Firm, Expands Management Team at The Wall Street Journal
11:38AM  Top 5 profitable Biotech stocks : September 23, 2016
10:04AM  What Are Analysts Recommendations for Gilead Sciences?
Sep-22-16 02:00PM  Biogen Bets on Nusinersen (BIIB, IONS) at Investopedia
08:04AM  Moves in Cancer Therapeutics among Recent Developments for Ionis
Sep-21-16 11:55AM  Amazon (AMZN), Charter Communications (CHTR) And 3 Other Hot Stocks That Billionaire Ken Griffin Is Bullish On at Insider Monkey
09:38AM  Gilead Sciences: Allergan's Next Target? at
08:04AM  Orphan Drug Designation among Latest Happenings at Ionis
Sep-20-16 03:01PM  Stocks Close Barely Higher Ahead Of Fed Announcement; Biotechs Aid Nasdaq
02:01PM  3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition at Motley Fool
10:20AM  Perrigo Could Rake In $2.8 Billion in Tysabri Divestitures, Analysts Say
09:05AM  Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen
Sep-19-16 01:16PM  Could This Alzheimers Disease Drug Really Be Worth $20 Billion? at Motley Fool
Sep-18-16 09:13AM  Marijuana Could Be the Answer to Curing Alzheimer's Disease, Study Shows at Motley Fool
Sep-17-16 11:41AM  Is This New Market the Biggest Investment Idea of the Decade? at Motley Fool
Sep-16-16 10:53AM  Biogen: You Mean There's Hope? at
Sep-15-16 07:30AM  New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA (Daclizumab) and Support Long-Term Safety Profile Business Wire
Sep-14-16 04:01PM  Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016 Business Wire
09:47AM  Biogen (BIIB) Stock Gains on Positive Multiple Sclerosis Drug Data
07:42AM  Biogen reports positive new data for multiple sclerosis treatment at MarketWatch
07:30AM  New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting Business Wire
Sep-13-16 04:10PM  Applied Genetics stock suffers record plunge to record low at MarketWatch
01:45PM  Why Applied Genetic Technologies Corp. Is Tanking Today at Motley Fool
10:04AM  Biogen Committed to Bolstering Its Strong Product Pipeline
08:04AM  Product Launches Are Part of Biogens Plans to Boost Revenues
07:05AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Sep-12-16 06:45PM  Traders pick biotech stocks as sector sees best day in months at CNBC
05:00PM  Buying biotech: 5 trades in pharma
04:10PM  How the Tides Are Turning in Alzheimer's Research at Motley Fool
03:32PM  Biotech: Four Catalysts for Four Stocks at
11:04AM  After Spinning Off Hemophilia Business, Whats Next for Biogen?
10:04AM  Whats behind Biogen Buyout Rumors?
08:04AM  Market Cheers FDAs Fast Tracking of BIIBs Alzheimers Treatment
08:00AM  Samsung Bioepis' SB4 (BRENZYS) Becomes First Etanercept Biosimilar to Receive Regulatory Approval in Canada Business Wire
Sep-09-16 03:04PM  Market Watches to See if Biogen Will Meet Its Raised Guidance
02:04PM  Here Are the Latest Analyst Recommendations for Biogen
12:53PM  Biogen Launches Flixabi To Raise Stakes In Biosimilar Wars (BIIB) at Investopedia
11:37AM  Biogens Latest Valuation Compared to Its Peers
Sep-08-16 02:53PM  Biogen: Be Like Celgene? at
01:23PM  Better Buy: Biogen Inc. vs. Gilead Sciences at Motley Fool
07:30AM  Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio Business Wire
Sep-07-16 02:04PM  Celgenes Enterprise Value to Earnings in Line with Peers
11:41AM  Understanding Celgenes Premium PE Valuation
11:10AM  These Stocks are Predicted to Outperform this Week According to Forcerank
11:10AM  These Stocks are Predicted to Outperform this Week According to Forcerank
09:30AM  Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled
Sep-06-16 04:51PM  Activision Hits High On Analyst Call, Qualcomm PT Hiked, Intel Upgraded, Biogen Cut
12:31PM  4 Stocks, 4 trades: GT, MDLZ & more
10:08AM  Gilead Sciences: Why is This Upgrade Different from All Other Upgrades? at
09:30AM  Here's what you missed on your summer vacation in life science news at
08:55AM  Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Devon Energy, Gilead, Mondelez, Urban Outfitters and More at 24/7 Wall St.
07:50AM  Biogen (BIIB) Stock Lower, Downgraded at Jefferies
07:40AM  Is Biogen's Rough Ride Over?
05:46AM  Biogen downgraded by Jefferies
Sep-05-16 08:04AM  Why Pfizers Enbrel Faces a Sales Decline
Sep-04-16 12:05PM  Is Biogen a Worthwhile Buyout Candidate? at Motley Fool
Sep-02-16 01:03PM  Time to look at biotechs?
11:27AM  Biogen: On the Fast Track at
09:40AM  Biogen (BIIB) Stock Climbs, Alzheimer's Treatment Gets Fast-Track Designation
09:33AM  Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Sep-01-16 06:53PM  [$$] Biogen's Alzheimer's Therapy Granted FDA Fast-Track Status at The Wall Street Journal
04:01PM  Biogens Investigational Alzheimers Disease Treatment Aducanumab Granted FDA Fast Track Designation Business Wire
04:01PM  Biogen to Present at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-31-16 01:13PM  Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogens Investigational Alzheimers Disease Treatment Aducanumab Business Wire
01:00PM  [$$] Biogen predicts preventive drug for Alzheimer's disease at Financial Times
Aug-30-16 03:00PM  Top 10 Biotech Stocks for 2016 (ALXN, ALNY) at Investopedia
08:27AM  Biogen Is Setting Up for a Rare Low-Risk Buying Opportunity
Aug-28-16 07:07AM  Time to Shift Your Focus
Aug-26-16 10:05AM  What Should We Expect from BioMarins Kuvan in 2016?
Aug-25-16 01:04PM  Whats BioMarins Expected Revenue Growth in 2016 and 2017?
11:04AM  AbbVie Expects to Launch Zinbryta in the US in August
09:30AM  Allergan, Humana, Biogen: Billionaires Favorite Healthcare Stocks For Q3 at Insider Monkey
08:40AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
Aug-24-16 02:09PM  Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug-20-16 08:34AM  9 Stocks Smart Investors Put Their Money in Last Quarter
Aug-18-16 09:06AM  Genzyme Continued to Boost Growth for Sanofi in 2Q16
09:04AM  Ozanimod May Prove to Be a Strong Growth Driver for Celgene
Aug-17-16 08:21AM  Better Buy: Amgen Inc. vs. Biogen at Motley Fool
Aug-16-16 03:48PM  Ionis Pharmaceuticals Inc Begins to Shift Focus at Motley Fool
Aug-15-16 07:17PM  Sarah Ketterer Takes 3 Positions in 2nd Quarter
05:00PM  Amid takeover rumors, Biogen gives details on hemophilia spinoff at
02:44PM  Top 3 Research Reports for August 15, 2016
09:15AM  Post Earnings Coverage as Perrigo Doubles Profit
09:13AM  Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Aug-12-16 06:07PM  Richard Snow Slashed Abercrombie & Fitch Stake in 2nd Quarter
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
06:30AM  Analysts: Gilead Should Divide Itself and Conquer
Aug-11-16 05:30PM  Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
12:34PM  ETFs with exposure to Biogen, Inc. : August 11, 2016
12:28PM  Valeant sinks on criminal probe
11:30AM  Heres what we know about Shires cost-cutting plans for the next three years at
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DORSA CAROLINEDirectorSep 22Option Exercise53.6427,5701,478,85544,663Sep 26 04:24 PM
DORSA CAROLINEDirectorSep 22Sale314.0027,5708,656,98017,093Sep 26 04:24 PM
SCANGOS GEORGE AChief Executive OfficerJul 21Sale280.0015743,96054,779Jul 22 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 25Sale280.0015743,96059,633May 27 08:59 AM
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.00636032,140Feb 25 05:05 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 23Option Exercise0.0057908,599Feb 25 04:59 PM
DiPietro KennethEVP Human ResourcesFeb 23Option Exercise0.0063604,237Feb 25 05:01 PM
Koppel AdamEVP, Strategy and Bus. Dev.Feb 23Option Exercise0.0030101,963Feb 25 05:02 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.006602,709Feb 25 05:09 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.00579027,143Feb 25 05:13 PM
SCANGOS GEORGE AChief Executive OfficerFeb 23Option Exercise0.002,964062,812Feb 25 04:51 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 17Sale256.16722184,9487,990Feb 19 04:18 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale256.16487124,75059,848Feb 19 04:20 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,31604,466Feb 17 06:00 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.003,859027,768Feb 17 05:53 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,05702,692Feb 17 05:54 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,274052,364Feb 10 04:19 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 09Sale246.54852210,0527,740Feb 10 04:17 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 08Option Exercise0.001,27809,018Feb 10 04:17 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,026029,666Feb 09 04:51 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70907,030Feb 09 04:48 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratDec 04Sale277.00441122,1577,740Dec 07 04:20 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsDec 02Sale289.144813,8797,875Dec 03 04:19 PM
DENNER ALEXANDER JDirectorOct 23Buy276.77100,00027,677,000310,000Oct 26 07:03 PM
DENNER ALEXANDER JDirectorOct 22Buy277.80210,00058,338,000210,000Oct 26 07:03 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 05Sale291.4326978,3958,094Oct 06 04:40 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 02Sale283.38417118,1698,363Oct 05 04:10 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 01Option Exercise0.001,939010,446Oct 05 04:10 PM